$7.4 Bil­lion Set­tle­ment With Purdue Pharma in Opi­oid Epidemic

Translate to Spanish or other 102 languages!

exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
exas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. Logo Source: Public Domain via Wikimedia Commons. Bad for illustration purposes
- Advertisement -

Texas Attorney General Ken Paxton announced that a bipartisan coalition of states and other parties reached a $7.4 billion settlement in principle with members of the Sackler family and their company Purdue Pharma, Inc. (“Purdue”) for their instrumental role in creating the opioid crisis. 

Purdue, under the Sacklers’ leadership, invented, manufactured, and aggressively marketed opioid products for decades, fueling waves of addiction and overdose deaths across the country. The settlement ends the Sacklers’ control of Purdue and their ability to sell opioids in the United States. Further, it will deliver funding directly to communities across the country over the next 15 years to support opioid addiction treatment, prevention, and recovery programs. The $7.4 billion settlement in principle, the nation’s largest settlement to date with individuals responsible for contributing to the opioid crisis, comes after the United States Supreme Court overturned a prior multistate settlement with the Sacklers and Purdue in June 2024.

“For years, I have aggressively worked to hold Purdue Pharma and other corporations accountable for their roles in creating and exacerbating the deadly opioid crisis that harmed so many Americans,” said Attorney General Paxton. “While nothing can restore the damage done, this settlement will provide Texans valuable resources to help prevent more opioid abuse. It was an honor to help lead these negotiations and I will never stop ensuring that justice is secured for those affected.” 

- Advertisement -

Attorney General Paxton has been a national leader in holding companies accountable for their roles in the opioid crisis, securing over $3 billion in settlements with Johnson & JohnsonWalmartWalgreensCVS, and other companies. 

Joining Attorney General Paxton in securing the settlement in principle are the attorneys general of California, Colorado, Connecticut, Delaware, Florida, Illinois, Massachusetts, New York, Oregon, Pennsylvania, Tennessee, Vermont, Virginia, and West Virginia.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.

DHR Health Burn Surgeon Urges Public to Avoid Preventable Risks

Many of the most serious burn and trauma injuries can be prevented by avoiding unnecessary risks, according to Dr. R. Dewayne Edwards, chief burn surgeon, surgical critical care and trauma surgeon at DHR Health, who said public awareness and timely medical care remain essential to improving patient outcomes.

Endocrine Society Outlines Strict Rules for Safe Testosterone Therapy

The Society’s Clinical Practice Guideline on testosterone replacement therapy in men with hypogonadism offers recommendations on appropriate testing and prescribing practices. 
- Advertisement -